Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cysteinyl Leukotriene Receptor 2 (CysLT2) is a G protein-coupled receptor that belongs to the leukotriene receptor family. It is activated by cysteinyl leukotrienes, primarily LTD4, LTC4, and LTE4, with LTD4 and LTC4 having similar potency. CysLT2 is expressed in various tissues including the heart, brain, adrenal glands, vascular endothelial cells, and airway epithelial cells. It plays a role in inflammation by modulating smooth muscle contraction, vascular permeability, and leukocyte activation. Its activation exacerbates vascular permeability and postischemia/reperfusion injury. A major challenge is the lack of selective antagonists for research and therapeutic use, limiting the understanding of its precise role compared to CysLT1.
Gq alpha subunit protein coupling leading to downstream signaling pathways (e.g., contraction or increased permeability)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cysteinyl Leukotriene Receptor 2 (CysLT2).